2024
Open and Endovascular Treatment of the Common Femoral Artery in a Tertiary Care Center
Wells N, Hundito A, Tuttle M, Alameddine D, Aboian E, Arhuidese I, Fischer U, Perez Lozada J, Guzman R, Ochoa Chaar C. Open and Endovascular Treatment of the Common Femoral Artery in a Tertiary Care Center. Journal Of Vascular Surgery 2024 PMID: 39442735, DOI: 10.1016/j.jvs.2024.10.027.Peer-Reviewed Original ResearchLower extremity revascularizationTreated with open surgeryPeripheral arterial diseaseCFA endarterectomyEndovascular therapyOpen surgeryEndovascular treatmentEndovascular lower extremity revascularizationTreated with endovascular therapyCompared to open surgeryAssociated with higher perioperative complicationsLower extremity revascularization proceduresPost-operative bleedingFemoral arteryImprove patient selectionKaplan-Meier analysisTertiary care centerTertiary-care centerLong-term outcomesEndovascular treatment of peripheral arterial diseaseLonger hospital lengthMALE-free survivalMultivariate logistic regressionTreatment of peripheral arterial diseaseCommon femoral artery
2021
Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient group